PipeCo Team

Amplifier Therapeutics™ is run by an accomplished team with deep and proven experience in clinical development and small molecule AMPK activators

Board of Directors

Martin Gunhaga

Director

CIO

Fort Knox AB

Read full bio

Martin Gunhaga

Director

Martin Gunhaga is the CIO at Fort Knox Förvaring AB, a Swedish single family office with private investments in 30+ companies throughout northern Sweden. Joined Fort Knox in 2011 after having spent 13 years within asset management at Handelsbanken, the last couple of years as head of advisory asset management and equity trading in northern Sweden. Extensive BOD experience and a humble participant in numerous business development journeys.

Gunnar Olsson, MD, PhD

Director

Read full bio

Gunnar Olsson, MD, PhD

Director

Gunnar Olsson, MD, PhD is a Board Director. Dr. Olsson brings more than 30 years’ experience in drug development, including 25 years at AstraZeneca. While at AstraZeneca Dr. Olsson held a number of senior roles in Global R&D including Senior VP and leader of the CV & GI Therapy Area. He is certified in Cardiology and Internal Medicine in hospitals associated with Karolinska Institutet, where he was adjunct professor for 12 years. In recent years Dr. Olsson has worked with innovative biotech companies in the Scandinavian region as board member or advisor. He is currently Chairman of the Board of IRLAB AB and Athera Biotechnologies AB and is a member of the Board of Gesynta AB.

James Peyer, PhD

Board Chairman

CEO

Cambrian Bio

Read full bio

James Peyer, PhD

Board Chairman

James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Bio. He also holds multiple board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. Dr. Peyer was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, Dr. Peyer was a biotech R& D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his BA with special honors from the University of Chicago.

Ruth Thieroff-Ekerdt, MD

Director

EVP, Clinical Development

Cambrian Bio

Read full bio

Ruth Thieroff-Ekerdt, MD

Director

Ruth Thieroff-Ekerdt, MD, serves as Executive Vice President Clinical Development at Cambrian Bio. Prior to joining Cambrian, she was Chief Medical Officer at Sojournix, and Acting CMO/Scientific Advisor at Organon. She also served as Chief Medical Officer at Aptalis, Strongbridge, Kaleido and held R& D positions of increasing responsibility at Bayer. She graduated as MD and Dr. med. from the Free University Berlin and specialized in Pharmacology and Clinical Pharmacology. She has over 30 years of experience in pharmaceutical R& D at all stages of discovery, development, and commercialization, with a successful track record of leading translational and development programs, submissions, and product launches in EU and US in various therapeutic areas and technologies. She also served as expert in the European Innovative Medicine Initiative and on the Scientific Advisory Board for Chr. Hansen. Dr. Thieroff-Ekerdt has published 28 scientific articles and conference contributions and is inventor/co-inventor of 31 patents.

Team

James Hall, MD, PhD

CEO

Read full bio

James Hall, MD, PhD

CEO

James Hall, MD, PhD, is the CEO of Amplifier Therapeutics. Dr. Hall brings extensive senior healthcare and life science experience, including 12 years with AstraZeneca. While there, he held a number of commercial, R&D and Business Development roles, including VP Global Marketing for the CV/GI Therapy Area, Global Product VP for Crestor and VP Evaluation for the CV/Metabolism/Renal Therapy Area. Prior to this he was a member of the Pharmaceutical /Medical Products practice at McKinsey & Co. He has a BM, BCh in Clinical Medicine and a D.Phil in Cell Physiology from Oxford University, where he was a Rhodes Scholar.

Jessica Ainscough

Senior Director

Clinical Operations

Cambrian Bio

Read full bio

Jessica Ainscough

Senior Director

Jessica Ainscough is the Senior Director of Clinical Operations for Cambrian Bio. Ainscough brings over 17 years of experience in the industry as a dedicated clinical operations and quality management leader. She has held leadership roles in clinical operations at Epizyme, Kadmon Holdings and ICON and in compliance management at Tesaro and Beth Israel Deaconess Medical Center in which she developed risk management programs. Ainscough has been at the forefront of clinical operations design and development and strategically bringing early stage clinical assets through to FDA approval.

Eva Berggren

CEO-Assistant and Administrator

Read full bio

Eva Berggren

CEO-Assistant and Administrator

Eva Berggren is the Administrator and Executive Assistant to the CEO at Amplifier Therapeutics. She brings over 20 years experience of pre-clinical and clinical drug development from Betagenon AB. While there, she conitributed to laboratory work, pre-clinical drug development and assistance in clinical development. She brings a broad experience in pre-clinical drug development, clinical CRO management and team/Business administration. Berggren holds a MS in Biomedicin from University at Umeå, Sweden.

Diana Brassard, PhD

Senior Director

R&D Project Management

Cambrian Bio

Read full bio

Diana Brassard, PhD

Senior Director

Diana Brassard, PhD is a scientist and R&D cross-functional, global program leader with strategic and tactical experience in both research and clinical development programs, preclinical to phase 3. She has experience with strategic and operational planning, project tracking, risk identification, cost oversight, budget forecasting, and resource management. Experience facilitating cross-functional teams to develop project development scenarios and to manage conflict resolution, and issue escalation. She has held strategic and operational responsibilities for senior leader stakeholder and external partner/vendor oversight at Sanofi and Takeda. Diana started her career at Schering-Plough in BioTechnology Development following an industrial post-doc.  She has a PhD in Biochemistry, Molecular Biology, and Cell Biology from Northwestern University and a AB in Biochemistry from Mount Holyoke College.

David Jacobs, MD

VP

Clinical Develoment

Read full bio

David Jacobs, MD

VP

Dr. Jacobs brings more than 20 years of leadership experience covering all aspects of drug development. He joins Amplifier from AGTC, at which he served as the Senior Vice President of Clinical Affairs and was responsible with the development and execution of clinical development strategy for multiple gene therapy candidates. Prior to AGTC, David was the Chief Development Officer at Oculis SA, where he was responsible for the for oversight, execution, and budget of all development functions including CMC, regulatory affairs, clinical development, and clinical operations. During his tenure, David developed and executed development plans and formulations for multiple phase 2 and phase 3 programs. Prior to his role at Oculis, Dr. Jacobs held drug development leadership positions at Daiichi-Sankyo, Johnson & Johnson, Aptalis Pharmaceuticals, King Pharmaceuticals, and Osmotica Pharmaceuticals.

Vrej Jubian, PhD

Director

API Mfg & Drug Product, CMC

Cambrian Bio

Read full bio

Vrej Jubian, PhD

Director

Vrej Jubian, PhD, is a Director, API Manufacturing and Drug Product, CMC. With over 25 years of experience in pharmaceutical, biotech and chemical industries, he brings expertise in chemical development of small organic molecules from the discovery stage to the clinic. Prior to joining Cambrian, he served in the Business Management group at Thermo Fisher’s API drug substance division providing technical assessments and solutions for clients looking to develop their clinical candidates. Before Thermo Fisher, he worked as the CMC Manager for Synaptic Pharmaceuticals and subsequently as a Principal Scientist for Lundbeck. He managed outsourcing activities for development programs and internal medchem projects. He also headed a scale-up lab and provided leadership in drug discovery projects where his group identified several drug development candidates targeting novel GPCRs for CNS therapeutics. Jubian received his PhD in organic chemistry from McGill University (Montreal, Canada) and completed his postdoctoral training at University of Pittsburgh.

Jasmine Malshe

Senior Manager

Business Operations

Cambrian Bio

Read full bio

Jasmine Malshe

Senior Manager

Jasmine Malshe is a Sr. Business Operations Manager at Cambrian Bio. She has over 12 years of operations experience in the Pharma/biotech and medical device industry. Malshe is experienced in processes improvements, continuous improvement, establishing new processes related to different aspects of operations. Prior to joining Cambrian, she was Sr. Advance Operations Manager at Hologic Inc, a medical device company focusing on and leading in women’s health. There, she led a team of Engineers and Project managers to establish framework and process to ensure successful launch of New Products into manufacturing and market. In one of her prior roles at Stryker Orthopedics she established a new department from scratch for end-to-end manufacturing of custom Implants for cancer patients. Malshe holds a MS in Biotechnology from University at Buffalo and BS in Pharmacy from University of Pune, India.

Erik Schneider

Director

Business Development

Cambrian Bio

Read full bio

Erik Schneider

Director

Erik Schneider is a Director of Business Development at Cambrian Bio. Previously, he was on the Business Development and Licensing team at Novartis, evaluating deal and portfolio strategy across cardiovascular, immunology, and neuroscience franchises. Prior to joining Novartis, Schneider was a consultant at CBPartners (now Trinity Life Sciences), with a focus on commercial and pricing strategy for new products. Schneider graduated from the College of the Holy Cross with a degree in Biochemistry.

Ruth Thieroff-Ekerdt, MD

EVP

Clinical Development

Cambrian Bio

Read full bio

Ruth Thieroff-Ekerdt, MD

EVP

Ruth Thieroff-Ekerdt, MD, is the Executive Vice President, Clinical Development at Cambrian Bio. Prior to joining Cambrian, she was Chief Medical Officer at Sojournix, and Acting CMO/Scientific Advisor at Organon. She also served as Chief Medical Officer at Aptalis, Strongbridge, Kaleido and held R& D positions of increasing responsibility at Bayer. She graduated as MD and Dr. med. from the Free University Berlin and specialized in Pharmacology and Clinical Pharmacology. She has over 30 years of experience in pharmaceutical R& D at all stages of discovery, development, and commercialization, with a successful track record of leading translational and development programs, submissions, and product launches in EU and US in various therapeutic areas and technologies. She also served as expert in the European Innovative Medicine Initiative and on the Scientific Advisory Board for Chr. Hansen. Dr. Thieroff-Ekerdt has published 28 scientific articles and conference contributions and is inventor/co-inventor of 31 patents.

Scientific Founders

Helena Edlund, PhD

Scientific Founder

Read full bio

Helena Edlund, PhD

Scientific Founder

Helena Edlund, PhD. is a Founder, Vice President, Head of Discovery, and Professor in Molecular Developmental Biology at Umeå Center for Molecular Medicine, University of Umeå. She has been a Visiting Professor at the Diabetes Research Institute, University of Miami School of Medicine, Miami, USA. Dr. H. Edlund has provided seminal information on transcription and signaling factors that control key aspects of pancreas development and beta-cell function. Dr. H. Edlund’s discoveries have raised considerable international recognition and have been honored by numerous national and international awards. Presently, Dr. H. Edlund heads a research team that uses genetic approaches and classical embryological techniques to study pancreas development and beta-cell function. Dr. H.Edlund is a member of the Swedish Royal Academy of Sciences and of EMBO. She has served on the scientific advisory board of Ontogeny Inc., Cambridge, USA.

Photo by Mattias Pettersson, Umeå University

Thomas Edlund, PhD

Scientific Founder

Read full bio

Thomas Edlund, PhD

Scientific Founder

Thomas Edlund is a Professor, Founder, and Chief Scientific Officer. Edlund serves as a professor of Molecular Genetics at University of Umeå. He was a co-founder of the biotech companies Symbicom AB and Uman Genomics AB and he has served on the scientific advisory board of Ontogeny Inc. Cambridge, USA. He has extensive experience of scientific strategy in biotech companies, in fundraising and other business activities. He was a Post-doc in Prof.William Rutter’s laboratory at UCSF, USA. He is an international renowned scientist in the study of the mechanism of development of the central nervous system and the mammalian pancreas and of the regulation of insulin gene expression. He is a member of the Swedish Royal Academy of Sciences and of EMBO and he has been honored by numerous national and international awards.

Photo by Mattias Pettersson, Umeå University

This is a headline that spans three lines stacked vertically